Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

InnoCare Pharma (9969.HK)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (HK$) Price Target (HK$) Rating
2022-02-2812.3623.20Neutral
2022-03-2812.0817.70Buy
2022-08-2211.5416.20Buy
2022-11-1411.7817.00Buy
2023-03-019.0214.10Buy
2023-03-288.1213.70Buy
2023-08-316.6412.60Buy
2023-11-146.5411.60Buy
2024-04-014.657.00Buy
2024-05-135.167.60Buy
2024-10-106.908.60Buy
2024-11-127.499.80Buy
2025-01-145.368.60Buy
2025-03-319.1412.30Buy
2025-05-149.4013.60Buy

Disclosures

  • Market capitalisation is calculated by multiplying the current share price by the sum of A and H shares.
  • UBS holds a long or short position of 0.5% or more of the listed shares of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.